Coronavirus response Abbott Coronavirus response Abbott Coronavirus response Abbott Coronavirus response Abbott

 
We are working across our company and in partnership with others to support communities worldwide with resources and technologies to fight this evolving threat. Getting new tests into the hands of frontline workers so people can receive the critical results they need. Ensuring continued access to medical devices, diagnostics, medicines and nutrition products without disruption. And supporting those affected by the pandemic. Until this fight is over, we will never quit.

Learn more about our efforts to tackle the coronavirus.

 

 

CUSTOMER SERVICE

 

ANTIGEN TESTING HELPS DETECT COVID-19 AT SCALE

Abbott's rapid antigen test — BinaxNOW COVID-19 Ag Card — is a reliable and affordable tool for detecting active COVID-19 infections at massive scale. The test is highly portable, easy-to-use, cost-effective, requires no instrumentation and provides results in 15 minutes.

The test also pairs with our optional, first-of-its-kind app named NAVICA that works on iPhone and Android devices and that's available at no charge. The app will allow people who test negative to get a temporary encrypted digital health pass with a QR code through a healthcare provider. The health pass is renewed each time a person takes a new test and will include the date of the latest test result. Organizations will be able to view and verify the information on a mobile device to facilitate entry into facilities along with hand-washing, social distancing, enhanced cleaning and mask-wearing. Those who test positive will get a message to quarantine and see a doctor.

OUR WORK ON COVID-19 TEST

 

OUR WORK ON COVID-19 TESTING

Testing is a critical part of addressing this threat. It's a battle that is fought on multiple fronts, from physicians’ offices and urgent care clinics to hospitals and molecular labs, from emergency departments to those hotspots where help is needed most.

Under FDA emergency use authorization (EUA), we are distributing six  COVID-19 tests:

  • For molecular testing, our rapid, point-of-care COVID-19 tests for our ID NOW system,  our m2000 RealTime molecular laboratory test as well as our Alinity m platform.
  • For antigen testing, our rapid and highly portable BinaxNOW COVID-19 Ag Card test, which pairs with our optional NAVICATM mobile app, allowing people who test negative to get a temporary digital health pass. The health pass is renewed each time a person takes a new test and will include the date of the latest test result.
  • For antibody testing, our blood test that runs on the ARCHITECT i1000SR and i2000SR laboratory instruments as well as the Alinity i.
HIGH VOLUME LAB TESTING

 

HIGH-VOLUME COVID-19 MOLECULAR LAB TESTING

Diagnostic testing is key to solving the complex puzzle of an infectious disease outbreak, by helping slow the spread of the virus. The Abbott RealTime SARS-CoV-2 test runs on our m2000 RealTime systems, which are already located in hospital and academic medical center labs and reference laboratories in the U.S. The FDA also granted an EUA to Alinity m molecular testing for COVID-19, expanding speed and efficiency on a machine that can run up to 1,080 tests in 24 hours. These high-volume platforms help healthcare providers meet the unprecedented demand for testing.

 Learn more about Abbott's m2000 platform.

 Learn more about Abbott's Alinity m platform.

 

WATCH NOW

DETECTING COVID-19 IN MIN

 

DETECTING COVID-19 IN AS LITTLE AS 5 MINUTES

Abbott’s ID NOW COVID-19 test is a vital weapon in this battle. It is a fast, molecular point-of-care test, one that can deliver results in as little as 5 minutes. Just as importantly, it can take portable testing outside of a traditional hospital and into physicians’ offices, urgent care clinics and other point-of-care settings.

 

Learn more about Abbott’s ID NOW platform.

 

SEE HOW IT WORKS

Antibody Testing

 

OUR COVID-19 TESTING EFFORTS: DETECTING ANTIBODIES

Our antibody tests can help play a role in the next step of fighting the COVID-19 pandemic head-on. Antibody tests determine if someone was exposed or infected. The body produces IgG antibodies in the late stages of infection and can remain for months or even years after recovery. Our IgG antibody test are available on ARCHITECT i1000SR, i2000SR and Alinity i laboratory instruments. 

Learn more about Abbott's ARCHITECT platform.

Learn more about Abbott's Alinity i platform.

Find where Abbott's COVID-19 antibody testing is available.

HOW CORONAVIRUS MOLECULAR TESTING WORKS HOW CORONAVIRUS MOLECULAR TESTING WORKS HOW CORONAVIRUS MOLECULAR TESTING WORKS HOW CORONAVIRUS MOLECULAR TESTING WORKS
COVID COVID COVID COVID
COVID-19 COVID-19 COVID-19 COVID-19
COVID-19 COVID-19 COVID-19 COVID-19
COVID-19 COVID-19 COVID-19 COVID-19

 

 

YOUR COVID-19 TESTING QUESTIONS ANSWERED

Find answers to frequently asked questions about Abbott's COVID-19 tests.

FAQ

 

 

The BinaxNOW COVID-19 Ag Test Card EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

 

The ID NOW COVID-19 EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

  

The SARS-CoV-2 IgG assay has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the detection of the IgG antibody against SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

The Abbott RealTime SARS-CoV-2 assay and the Alinity m SARS-CoV-2 assay have not been FDA cleared or approved. These tests have been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories. These tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?